Affinity O
States O
of O
Striatal O
Dopamine O
D2 O
Receptors O
in O
Antipsychotic-Free O
Patients O
with O
Schizophrenia O
Abstract O
Background O
Dopamine O
D2 O
receptors O
are O
reported O
to O
have O
high-affinity O
( O
D2High O
) O
and O
low-affinity O
( O
D2Low O
) O
states O
. O

Although O
an O
increased O
proportion O
of O
D2High O
has O
been O
demonstrated O
in O
animal O
models O
of O
schizophrenia O
, O
few O
clinical O
studies O
have O
investigated O
this O
alteration O
of O
D2High O
in O
schizophrenia O
in O
vivo O
. O

Methods O
Eleven O
patients O
with O
schizophrenia O
, O
including O
10 O
antipsychotic-naive O
and O
1 O
antipsychotic-free O
individuals O
, O
and O
17 O
healthy O
controls O
were O
investigated O
. O

Psychopathology O
was O
assessed O
by O
Positive O
and O
Negative O
Syndrome O
Scale O
, O
and O
a O
5-factor O
model O
was O
used O
. O

Two O
radioligands O
, O
[ O
11C O
] O
raclopride O
and O
[ O
11C O
] O
MNPA O
, O
were O
employed O
to O
quantify O
total O
dopamine O
D2 O
receptor O
and O
D2High O
, O
respectively O
, O
in O
the O
striatum O
by O
measuring O
their O
binding O
potentials O
. O

Binding O
potential O
values O
of O
[ O
11C O
] O
raclopride O
and O
[ O
11C O
] O
MNPA O
and O
the O
binding O
potential O
ratio O
of O
[ O
11C O
] O
MNPA O
to O
[ O
11C O
] O
raclopride O
in O
the O
striatal O
subregions O
were O
statistically O
compared O
between O
the O
2 O
diagnostic O
groups O
using O
multivariate O
analysis O
of O
covariance O
controlling O
for O
age O
, O
gender O
, O
and O
smoking O
. O

Correlations O
between O
binding O
potential O
and O
Positive O
and O
Negative O
Syndrome O
Scale O
scores O
were O
also O
examined O
. O

Results O
Multivariate O
analysis O
of O
covariance O
demonstrated O
a O
significant O
effect O
of O
diagnosis O
( O
schizophrenia O
and O
control O
) O
on O
the O
binding O
potential O
ratio O
( O
P=.018 O
) O
, O
although O
the O
effects O
of O
diagnosis O
on O
binding O
potential O
values O
obtained O
with O
either O
[ O
11C O
] O
raclopride O
or O
[ O
11C O
] O
MNPA O
were O
nonsignificant O
. O

Posthoc O
test O
showed O
that O
the O
binding O
potential O
ratio O
was O
significantly O
higher O
in O
the O
putamen O
of O
patients O
( O
P=.017 O
) O
. O

The O
Positive O
and O
Negative O
Syndrome O
Scale O
“ O
depressed O
” O
factor O
in O
patients O
was O
positively O
correlated O
with O
binding O
potential O
values O
of O
both O
ligands O
in O
the O
caudate O
. O

Conclusions O
The O
present O
study O
indicates O
the O
possibilities O
of O
: O
( O
1 O
) O
a O
higher O
proportion O
of O
D2High O
in O
the O
putamen O
despite O
unaltered O
amounts O
of O
total O
dopamine O
D2 O
receptors O
; O
and O
( O
2 O
) O
associations O
between O
depressive O
symptoms O
and O
amounts O
of O
caudate O
dopamine O
D2 O
receptors O
in O
patients O
with O
schizophrenia O
. O

Methods O
Participants O
A O
total O
of O
11 O
patients O
with O
schizophrenia O
( O
4 O
men O
and O
7 O
women O
) O
were O
recruited O
from O
affiliated O
hospitals O
or O
clinics O
. O

Seventeen O
healthy O
controls O
( O
8 O
men O
and O
9 O
women O
) O
were O
recruited O
by O
the O
National O
Institute O
of O
Radiological O
Sciences O
, O
Chiba O
, O
Japan O
, O
for O
participation O
in O
this O
study O
. O

The O
patient O
group O
was O
comprised O
of O
10 O
antipsychotic-naive O
patients O
( O
one O
had O
taken O
benzodiazepines O
the O
night O
before O
her O
PET O
scans O
) O
and O
1 O
patient O
who O
had O
been O
antipsychotic-free O
for O
2 O
years O
after O
1-year O
treatment O
with O
aripiprazole O
. O

All O
patients O
fulfilled O
the O
diagnostic O
criteria O
for O
schizophrenia O
according O
to O
DSM-IV O
. O

None O
of O
the O
patients O
were O
comorbid O
with O
other O
neuropsychiatric O
disorders O
or O
had O
substance O
abuse O
. O

Psychopathology O
was O
assessed O
using O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
, O
and O
a O
5-factor O
model O
was O
used O
to O
calculate O
PANSS O
subscale O
scores O
( O
positive O
, O
negative O
, O
disorganized/concrete O
, O
excited O
, O
and O
depressed O
factors O
) O
. O

The O
healthy O
control O
volunteers O
were O
recruited O
by O
public O
notices O
. O

They O
had O
no O
history O
of O
psychiatric O
disease O
, O
neurological O
injury O
or O
disease O
, O
severe O
medical O
diseases O
, O
substance O
abuse O
that O
may O
affect O
brain O
functions O
, O
or O
first-degree O
relatives O
suffering O
from O
psychotic O
episodes O
. O

All O
the O
diagnostic O
interviews O
and O
PANSS O
ratings O
were O
conducted O
by O
trained O
psychiatrists O
. O

Table O
1 O
presents O
the O
participants O
’ O
demographic O
information O
. O

This O
study O
was O
approved O
by O
the O
Radiation O
Drug O
Safety O
Committee O
and O
the O
Institutional O
Review O
Board O
of O
the O
National O
Institute O
of O
Radiological O
Sciences O
, O
Japan O
, O
and O
was O
carried O
out O
in O
accordance O
with O
the O
Code O
of O
Ethics O
of O
the O
World O
Medical O
Association O
. O

After O
complete O
description O
of O
the O
study O
, O
written O
informed O
consent O
was O
obtained O
from O
all O
participants O
. O

Data O
were O
collected O
between O
April O
2008 O
and O
October O
2016 O
. O

PET O
Procedures O
All O
subjects O
underwent O
2 O
PET O
scans O
on O
the O
same O
day O
, O
one O
with O
[ O
11C O
] O
raclopride O
and O
the O
other O
with O
[ O
11C O
] O
MNPA O
, O
except O
1 O
control O
subject O
who O
took O
the O
2 O
scans O
on O
separate O
days O
due O
to O
technical O
trouble O
. O

[ O
11C O
] O
MNPA-PET O
preceded O
[ O
11C O
] O
raclopride-PET O
in O
10 O
patients O
and O
11 O
controls O
, O
and O
[ O
11C O
] O
raclopride-PET O
was O
followed O
by O
[ O
11C O
] O
MNPA-PET O
in O
1 O
patient O
and O
6 O
controls O
. O

After O
i.v O
. O

rapid O
bolus O
injection O
of O
[ O
11C O
] O
raclopride O
, O
a O
PET O
scan O
was O
performed O
for O
60 O
minutes O
. O

Similarly O
, O
after O
i.v O
. O

rapid O
bolus O
injection O
of O
[ O
11C O
] O
MNPA O
, O
a O
PET O
scan O
was O
performed O
for O
90 O
minutes O
. O

The O
time O
interval O
between O
initiations O
of O
the O
first O
and O
second O
PET O
scans O
was O
120 O
minutes O
or O
longer O
. O

For O
both O
PET O
scans O
, O
3-dimensional O
dynamic O
PET O
data O
were O
acquired O
with O
a O
Siemens O
ECAT O
Exact O
HR+ O
system O
( O
CTI/Siemens O
) O
, O
which O
provides O
63 O
sections O
with O
an O
axial O
field O
of O
view O
of O
15.5 O
cm O
. O

PET O
images O
were O
reconstructed O
with O
a O
filtered O
back-projection O
method O
with O
corrections O
for O
attenuation O
and O
scatter O
. O

The O
reconstructed O
in-plane O
resolution O
was O
7.5 O
mm O
full-width O
at O
half-maximum O
. O

A O
10-minute O
transmission O
scan O
using O
a O
68Ge/68Ga O
line O
source O
was O
performed O
before O
each O
PET O
scan O
for O
attenuation O
correction O
. O

A O
thermoplastic O
head O
fixation O
device O
was O
used O
to O
minimize O
head O
movement O
during O
PET O
scanning O
. O

The O
dynamic O
scans O
consisted O
of O
twelve O
20-second O
frames O
, O
sixteen O
60-second O
frames O
, O
and O
ten O
240-second O
frames O
for O
[ O
11C O
] O
raclopride O
, O
and O
nine O
20-second O
frames O
, O
five O
60-second O
frames O
, O
four O
120-second O
frames O
, O
eleven O
240-second O
frames O
, O
and O
six O
300-second O
frames O
for O
[ O
11C O
] O
MNPA O
. O

MRI O
Procedures O
Because O
of O
replacements O
of O
MRI O
machines O
during O
this O
study O
, O
3 O
types O
of O
MRI O
devices O
were O
used O
depending O
on O
the O
time O
of O
participant O
recruitment O
. O

For O
the O
initial O
4 O
patients O
and O
7 O
controls O
, O
MR O
images O
were O
acquired O
with O
a O
1.5-T O
MR O
scanner O
( O
Intera O
, O
Philips O
Medical O
Systems O
) O
. O

3D O
volumetric O
acquisition O
of O
a O
T1-weighted O
gradient O
echo O
sequence O
produced O
a O
gapless O
series O
of O
thin O
transverse O
sections O
( O
TE O
9.2 O
ms O
, O
TR O
21 O
ms O
, O
flip O
angle O
30° O
, O
field O
of O
view O
256 O
mm O
, O
acquisition O
matrix O
256 O
× O
256 O
, O
slice O
thickness O
1 O
mm O
) O
. O

Then O
, O
for O
the O
next O
6 O
patients O
, O
a O
3-T O
MR O
scanner O
( O
Sigma O
HDx O
, O
General O
Electric O
) O
was O
used O
. O

3D O
volumetric O
acquisition O
of O
a O
T1-weighted O
3-dimensional O
fast O
spoiled O
gradient-recalled O
acquisition O
in O
the O
steady-state O
sequence O
produced O
a O
gapless O
series O
of O
thin O
transverse O
sections O
( O
TE O
2.8 O
ms O
, O
TR O
7.0 O
ms O
, O
flip O
angle O
8° O
, O
field O
of O
view O
260 O
mm O
, O
acquisition O
matrix O
256 O
× O
256 O
, O
slice O
thickness O
1 O
mm O
) O
. O

Finally O
, O
for O
1 O
patient O
and O
10 O
controls O
, O
T1-weighted O
MR O
images O
were O
obtained O
with O
another O
3-T O
MR O
scanner O
( O
MAGNETOM O
Verio O
, O
Siemens O
) O
. O

3D O
volumetric O
acquisition O
of O
a O
T1-weighted O
gradient O
echo O
sequence O
produced O
a O
gapless O
series O
of O
thin O
sagittal O
sections O
( O
TE O
1.95 O
ms O
, O
TR O
2300 O
ms O
, O
TI O
900 O
ms O
, O
flip O
angle O
9° O
, O
field O
of O
view O
250 O
mm O
, O
acquisition O
matrix O
256×256 O
, O
slice O
thickness O
1 O
mm O
) O
. O

Region O
of O
Interest O
( O
ROI O
) O
Definition O
All O
ROIs O
used O
in O
our O
analyses O
were O
initially O
defined O
on O
a O
standard O
anatomic O
orientation O
( O
MNI O
standard O
space O
; O
Montreal O
Neurological O
Institute O
) O
. O

Striatum O
ROIs O
( O
caudate O
, O
putamen O
, O
and O
ventral O
striata O
) O
were O
defined O
using O
a O
striatum O
anatomical O
atlas O
. O

A O
cerebellum O
ROI O
was O
defined O
with O
a O
probabilistic O
cerebellar O
atlas O
, O
excluding O
the O
vermis O
. O

These O
ROIs O
were O
transformed O
into O
individual O
MR O
spaces O
with O
transformation O
matrices O
calculated O
with O
the O
“ O
normalize O
” O
function O
of O
statistical O
parametric O
mapping O
software O
( O
SPM12 O
; O
Wellcome O
Department O
of O
Imaging O
Neuroscience O
) O
and O
were O
thresholded O
using O
FreeSurfer O
’ O
s O
automated O
anatomical O
segmentation O
to O
exclude O
neighboring O
white O
matter O
, O
ventricles O
, O
and O
non-brain O
regions O
. O

Time-activity O
curves O
for O
each O
ROI O
were O
extracted O
by O
applying O
these O
ROIs O
to O
individual O
dynamic O
PET O
images O
based O
on O
the O
transformation O
parameters O
for O
the O
coregistration O
of O
MR O
images O
to O
the O
PET O
spaces O
using O
PMOD O
software O
ver O
. O

3.7 O
( O
PMOD O
Technologies O
Ltd O
) O
. O

Quantification O
of O
Total O
D2R O
and O
D2High O
Availabilities O
in O
the O
Striatum O
Availabilities O
of O
striatal O
total O
D2R O
and O
D2High O
were O
quantified O
as O
binding O
potentials O
relative O
to O
the O
nondisplaceable O
tissue O
( O
BPND O
) O
of O
[ O
11C O
] O
raclopride O
and O
[ O
11C O
] O
MNPA O
, O
respectively O
. O

[ O
11C O
] O
raclopride O
BPND O
and O
[ O
11C O
] O
MNPA O
BPND O
were O
calculated O
for O
each O
ROI O
using O
a O
3-parameter O
simplified O
reference O
tissue O
model O
and O
cerebellar O
cortex O
as O
reference O
tissue O
, O
which O
has O
negligible O
density O
of O
D2R O
. O

BPND O
was O
defined O
as O
follows O
: O
where O
fND O
is O
the O
free O
fraction O
of O
radioligand O
in O
the O
nondisplaceable O
tissue O
compartment O
and O
Bavail O
indicates O
the O
neuroreceptor O
density O
. O

All O
kinetic O
analyses O
were O
performed O
using O
PMOD O
software O
ver O
. O

3.7 O
. O

Statistical O
Analysis O
Statistical O
analyses O
were O
conducted O
with O
SPSS O
23.0 O
( O
SPSS O
Inc O
) O
. O

First O
, O
MANCOVA O
was O
applied O
to O
examine O
group O
differences O
in O
: O
( O
1 O
) O
BPND O
of O
[ O
11C O
] O
raclopride O
; O
( O
2 O
) O
BPND O
of O
[ O
11C O
] O
MNPA O
; O
and O
( O
3 O
) O
the O
BPND O
ratio O
( O
ratio O
of O
[ O
11C O
] O
MNPA O
BPND O
to O
[ O
11C O
] O
raclopride O
BPND O
) O
in O
3 O
striatal O
ROIs O
( O
caudate O
, O
putamen O
, O
and O
ventral O
striata O
) O
, O
separately O
. O

A O
fixed O
factor O
was O
diagnosis O
( O
patients O
= O
1 O
, O
controls O
= O
0 O
) O
. O

Nuisance O
covariates O
were O
defined O
as O
age O
, O
gender O
, O
and O
smoking O
state O
( O
smoker O
= O
1 O
, O
nonsmoker O
= O
0 O
) O
to O
control O
for O
their O
potential O
effects O
on O
D2Rs O
. O

Statistical O
significance O
threshold O
was O
defined O
as O
P O
< O
.05 O
( O
2-tailed O
) O
. O

Second O
, O
correlational O
analyses O
were O
performed O
between O
the O
BPND O
values O
mentioned O
above O
and O
each O
of O
the O
PANSS O
factor O
scores O
( O
positive O
, O
negative O
, O
disorganized/concrete O
, O
excited O
, O
and O
depressed O
factors O
) O
in O
patients O
. O

The O
statistical O
threshold O
was O
set O
at O
P O
< O
.05 O
with O
Bonferroni O
correction O
for O
the O
3 O
striatal O
subregions O
( O
caudate O
, O
putamen O
, O
and O
ventral O
striata O
) O
, O
as O
in O
previous O
studies O
. O

Because O
of O
the O
small O
sample O
size O
and O
exploratory O
nature O
of O
this O
study O
, O
corrections O
were O
not O
applied O
for O
multiple O
comparisons O
of O
the O
5 O
PANSS O
factor O
scores O
and O
the O
3 O
binding O
parameters O
( O
[ O
11C O
] O
raclopride O
BPND O
, O
[ O
11C O
] O
MNPA O
BPND O
, O
and O
their O
ratio O
) O
. O

In O
case O
significant O
correlations O
were O
found O
, O
partial O
correlation O
analyses O
were O
also O
performed O
, O
controlling O
for O
age O
, O
gender O
, O
smoking O
state O
, O
or O
duration O
of O
illness O
. O

Statistical O
significance O
threshold O
was O
defined O
as O
P O
< O
.05 O
( O
2-tailed O
) O
. O

